Several other equities research analysts also recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, August 12th. Zacks Investment Research downgraded Agile Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 17th. Finally, Maxim Group reiterated a “buy” rating and issued a $8.00 price target on shares of Agile Therapeutics in a report on Wednesday, September 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.00.
Shares of AGRX stock opened at $3.78 on Tuesday. Agile Therapeutics has a 1 year low of $0.35 and a 1 year high of $4.77. The company has a debt-to-equity ratio of 0.20, a current ratio of 13.67 and a quick ratio of 13.67. The stock’s 50 day simple moving average is $2.91 and its two-hundred day simple moving average is $2.59. The company has a market cap of $329.99 million, a PE ratio of -9.45 and a beta of 1.48.
A number of hedge funds have recently bought and sold shares of AGRX. Perceptive Advisors LLC boosted its holdings in Agile Therapeutics by 33.6% in the 1st quarter. Perceptive Advisors LLC now owns 15,919,325 shares of the specialty pharmaceutical company’s stock worth $29,611,000 after buying an additional 3,999,400 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Agile Therapeutics during the 1st quarter worth approximately $2,232,000. Nuveen Asset Management LLC acquired a new position in shares of Agile Therapeutics during the 2nd quarter worth approximately $888,000. BlackRock Inc. boosted its holdings in shares of Agile Therapeutics by 31.6% during the 1st quarter. BlackRock Inc. now owns 1,258,808 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after purchasing an additional 302,596 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Agile Therapeutics during the 2nd quarter worth approximately $676,000. Institutional investors own 44.10% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Featured Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.